@article{bylicki:hal-04016683, TITLE = {{Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018}}, AUTHOR = {Bylicki, Olivier and Tomasini, Pascale and Radj, Gervais and Guisier, Florian and Monnet, Isabelle and Ricordel, Charles and Bigay-Game, Laurence and Geier, Margaux and Chouaid, Christos and Daniel, Catherine and Swalduz, Aurelie and Toffart, Anne-Claire and Doubre, Helene and Peloni, Jean-Michel and Moreau, Diane and Subtil, Fabien and Grellard, Jean-Michel and Castera, Marie and Clarisse, Benedicte and Martins-Lavinas, Pedro-Henrique and Decroisette, Chantal and Greillier, Laurent}, URL = {https://univ-rennes.hal.science/hal-04016683}, JOURNAL = {{European Journal of Cancer}}, PUBLISHER = {{Elsevier}}, VOLUME = {183}, PAGES = {38-48}, YEAR = {2023}, MONTH = Apr, DOI = {10.1016/j.ejca.2023.01.014}, KEYWORDS = {EGFR-mutation ; Immunotherapy ; Non-small cell lung cancer ; Resistance}, PDF = {https://univ-rennes.hal.science/hal-04016683/file/Bylicki%20et%20al.%20-%202023%20-%20Atezolizumab%20with%20or%20without%20bevacizumab%20and%20plati.pdf}, HAL_ID = {hal-04016683}, HAL_VERSION = {v1}, }